WHO/Daniel Hodgson
© Credits

Measles

    Overview

    Measles is a highly contagious viral disease. It remains an important cause of death among young children globally, despite the availability of a safe and effective vaccine.

    While vaccination has prevented an estimated 60 million deaths between 2000–2023, measles is still common in many developing countries, particularly in parts of Africa and Asia. An estimated 107 500 people died from measles in 2023. The overwhelming majority (more than 95%) of measles deaths occur in countries with low per capita incomes and weak health infrastructures.

    Member States in all WHO Regions have adopted measles elimination goals. WHO is the lead technical agency responsible for coordination of immunization and surveillance activities supporting all countries to achieve these goals.

    Symptoms

    Measles is transmitted via droplets from the nose, mouth or throat of infected persons. Initial symptoms, which usually appear 10–14 days after infection, include high fever, a runny nose, bloodshot eyes, and tiny white spots on the inside of the mouth. Several days later, a rash develops, starting on the face and upper neck and gradually spreading downwards.

    Severe measles is more likely among poorly nourished young children, especially those with insufficient vitamin A, or whose immune systems have been weakened by HIV/AIDS or other diseases. The most serious complications include blindness, encephalitis (an infection that causes brain swelling), severe diarrhoea and related dehydration, and severe respiratory infections such as pneumonia.

    Prevention

    Routine measles vaccination for children, combined with mass immunization campaigns in countries with low routine coverage, are key public health strategies to reduce global measles deaths.

    The measles vaccine has been in use since the 1960s. It is safe, effective and inexpensive. WHO recommends immunization for all susceptible children and adults for whom measles vaccination is not contraindicated. Reaching all children with 2 doses of measles vaccine, either alone, or in a measles-rubella (MR), measles-mumps-rubella (MMR), or measles-mumps-rubella-varicella (MMRV) combination, should be the standard for all national immunization programmes.

    Latest publications

    All →
    Targeted and selective strategies in measles and rubella vaccination campaigns: Interim guidance

    The World Health Organization provides regional and national strategies and operational plans that aim to support countries in work to achieve measles...

    Tenth South-East Asia Regional Meeting of Virologists of the Measles and Rubella Laboratory Network

    Objectives of the meetingTo conduct a detailed desk review of performance of the measles and rubella (MR) laboratories against standard global monitoring...

    Ninth Meeting of the WHO South-East Asia Regional Verification Commission for measles and rubella elimination

    The Regional Verification Commission (RVC) for measles and rubella elimination for the WHO South-East Asia Region was established by the Regional Director...

    Strategic Plan for measles and rubella elimination and sustenance in the WHO South-East Asia Region: 2024–2028

    The WHO South-East Asia Regional Vaccine Implementation Plan 2022–2026 envisions measles and rubella elimination in the Region by 2026. This Plan...